ScripDisappointing news appeared to overflow in the South Korean biotech sector in the second quarter amid multiple returned assets from global partners, a lack of major new out-licensing deals, as well as
ScripWhile global pharma firms are rolling out advanced gene and cell therapies, as well as aggressively making R&D investments in the space to grab the leading position in the burgeoning market, South Kor